To investigate whether there is an association between local or systemic IgG and IgA responses against human papillomavirus (HPV) type 16 virus-like particles (VLP) containing L1 and L2 and the possible influence of these responses on clearance of HPV-16 and its associated lesions, cervical mucus samples from 125 patients and plasma samples from 100 patients, all participating in a non-intervention cohort study of women with abnormal cytology, were analysed. The results show that local IgG and IgA HPV-16 VLP-specific antibodies do not correlate with virus clearance. However, systemic IgG responses were more frequently detected in patients with a persistent infection (11/24) compared with patients with cleared HPV-16 infections (3/28, P = 0.006). Furthermore, the ultimate development of high-grade lesions was associated with systemic VLP-specific IgG reactivity (P = 0.026). By contrast, systemic IgA responses were correlated with virus clearance (7/28 clearance compared with 1/24 persistence patients, P = 0.06). This correlation was statistically significant when only those clearance patients who tested HPV-16 DNA-positive at more than one visit were included in the analysis (5/11 compared with 1/24, P = 0.007). As these systemic IgA responses were not accompanied by local IgA responses, the systemic IgA responses in HPV-16 clearance patients are suggested to be a by-product of a successful cellular immune response induced at the local lymph nodes, mediated by cytokines.
BoschF. X.,
ManosM. M.,
MunozN.,
ShermanM.,
JansenA. M.,
PetoJ.,
SchiffmanM. H.,
MorenoV.,
KurmanR.,
ShahK. V.1995; Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. Journal of the National Cancer Institute 87:796–802
BraunL.,
DurstM.,
MikumoR.,
GruppusoP.1990; Differential response of nontumorigenic and tumorigenic human papillomavirus type 16-positive epithelial cells to transforming growth factor β 1. Cancer Research 50:7324–7332
de GruijlT. D.,
BontkesH. J.,
WalboomersJ. M. M.,
SchillerJ. T.,
StukartM. J.,
GrootB. J.,
ChabaudM. M. R.,
RemminkA. J.,
VerheijenR. H. M.,
HelmerhorstT. J. M.,
MeijerC. J. L. M.,
ScheperR. J.1997; Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. Journal of the National Cancer Institute 89:630–638
de GruijlT. D.,
BontkesH. J.,
WalboomersJ. M. M.,
CoursagetP.,
StukartM. J.,
DupuyC.,
KueterE.,
VerheijenR. H. M.,
HelmerhorstT. J. M.,
Duggan-KeenM. F.,
SternP. L.,
MeijerC. J. L. M.,
ScheperR. J.1999; Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome. Journal of General Virology 80:399–408
de Roda HusmanA.-M.,
WalboomersJ. M. M.,
van den BruleA. J. C.,
MeijerC. J. L. M.,
SnijdersP. J. F.1995; The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. Journal of General Virology 76:1057–1062
DillnerJ.,
KallingsI.,
BrihmerC.,
SikströmB.,
KoskelaP.,
LehtinenM.,
SchillerJ. T.,
SappM.,
MardhP. A.1996; Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. Journal of Infectious Diseases 173:1394–1398
ElfgrenK.,
BistolettiP.,
DillnerL.,
WalboomersJ. M.,
MeijerC. J.,
DillnerJ.1996; Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. American Journal of Obstetrics and Gynecology 174:937–942
HoL.,
TerryG.,
MansellB.,
ButlerB.,
SingerA.1994; Detection of DNA and E7 transcripts of human papillomavirus types 16, 18, 31 and 33, TGF-β and GM-CSF transcripts in cervical cancers and precancers. Archives of Virology 139:79–85
IARC1995Monographs on the Evaluation of the Carcinogenic Risks to Humans vol 64 The Human Papillomavirus, Lyon; International Agency for Research on Cancer:
KirnbauerR.,
TaubJ.,
GreenstoneH.,
RodenR.,
DürstM.,
GissmannL.,
LowyD. R.,
SchillerJ. T.1993; Efficient self-assembly of human papillomavirus type 16 Ll and L1-L2 into virus-like particles. Journal of Virology 67:6929–6936
KirnbauerR.,
HubbertN. L.,
WheelerC. M.,
BeckerT. M.,
LowyD. R.,
SchillerJ. T.1994; A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. Journal of the National Cancer Institute 86:494–499
LagaM.,
IcenogleJ. P.,
MarsellaR.,
ManokaA. T.,
NzilaN.,
RyderR. W.,
VermundS. H.,
HeywardW. L.,
NelsonA.,
ReeveW. C.1992; Genital papillomavirus infection and cervical dysplasia: opportunistic complications of HIV infection. International Journal of Cancer 48:682–688
MelkertP. W.,
HopmanE.,
van den BruleA. J.,
RisseE. K.,
van DiestP. J.,
BlekerO. P.,
HelmerhorstT.,
SchipperM. E.,
MeijerC. J. L. M.,
WalboomersJ. M. M.1993; Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. International Journal of Cancer 53:919–923
RemminkA. J.,
WalboomersJ. M. M.,
HelmerhorstT. J. M.,
VoorhorstF. J.,
RozendaalL.,
RisseE. K. J.,
MeijerC. J. L. M.,
KenemansP.1995; The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. International Journal of Cancer 61:306–311
RodenR. B. S.,
HubbertN. L.,
KirnbauerR.,
ChristensenN. D.,
LowyD. R.,
SchillerJ. T.1996; Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. Journal of Virology 70:3298–3301
SasagawaT.,
YamazakiH.,
DongY. Z.,
SatakeS.,
TatenoM.,
InoueM.1998; Immunoglobulin-A and -G responses against viruslike particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions. International Journal of Cancer 75:529–535
StricklerH. D.,
SchiffmanM. H.,
EklundC.,
GlassA. G.,
ScottD. R.,
ShermanM. E.,
WacholderS.,
KurmanR. J.,
ManosM. M.,
SchillerJ. T.,
DillnerJ.1997; Evidence for at least two distinct groups of humoral immune reactions to papillomavirus antigens in women with squamous intraepithelial lesions. Cancer Epidemiology, Biomarkers & Prevention 6:183–188
Van GinkelF. W.,
VanCottJ. L.,
KiyonoH.,
McGheeJ. R.1997; Mucosal immunity to human papillomavirus in the female reproductive tract. Papillomavirus Report 8:1–10
WangZ.,
HanssonB. G.,
ForslundO.,
DillnerL.,
SappM.,
SchillerJ. T.,
BjerreB.,
DillnerJ.1996; Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA. Journal of Clinical Microbiology 34:3056–3062
WideroffL.,
SchiffmanM. H.,
NonnenmacherB.,
HubbertN. L.,
KirnbauerR.,
GreerC. E.,
LowyD. R.,
LorinczA. T.,
ManosM. M.,
GlassA. G.,
ScottD. R.,
ShermanM. E.,
KurmanR. J.,
BucklandJ.,
LaroneR. E.,
SchillerJ.1995; Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. Journal of Infectious Diseases 172:1425–1430
WoodworthC. D.,
LichtiU.,
SimpsonS.,
EvansC. H.,
DiPaoloJ. A.1992; Leukoregulin and gamma-interferon inhibit human papillomavirus type 16 gene transcription in human papillomavirus-immortalized human cervical cells. Cancer Research 52:456–463